Another phase III trial is comparing chemotherapy combined with crenolanib vs. chemotherapy alone in the relapse/refractory setting in patients with mutated FLT3-ITD AML (NCT02298166). This evidence concerns the gene FLT3 and acute myeloid leukemia.